

NC- MEDI-CAPS LIMITED

Regd. Office & Works :
Mhow-Neemuch Road, Sector-1,
Pithampur- 454 775, Distt. Dhar,
Madhya Pradesh, INDIA

CIN : L24232MP1983PLC002231

Phone : + 91-7292-424242
Fax. : + 91-7292-407387
E-mail : info@medicaps.com
sales@medicaps.com
investors@medicaps.com
Website : www.medicaps.com

MCL/SE/2018-19

14th November, 2018

Online filing at: www.listing.bseindia.com

To,
The General Manager
DCS-CRD
BSE Ltd.
PhirozeJeejeebhoy Towers
Dalal Street, Fort
MUMBAI - 400001

BSE Code: 523144

Sub: Submission of Standalone Unaudited Financial Results along with Limited Review Report thereon by Statutory Auditors for Quarter/Half-Year ended on 30th September, 2018 in accordance with Regulation 33 of the SEBI (LODR) Regulations, 2015.

Dear Sir/Madam,

This is in continuation of our letter no. MCL/SE/18-19 dated 01st November, 2018 regarding intimation of holding 03/2018-19 Meeting of the Board of Directors on **Wednesday, 14th November, 2018 at 03:00 P.M.** for consideration and approval of the Standalone Unaudited Financial Results of the Company for Quarter/ Half-Year ended on **30th September, 2018.**

Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, we are pleased to submit the Standalone Unaudited Financial Results along with Limited Review Report thereon by Statutory Auditors thereon for the Quarter/Half-Year ended on **30th September, 2018**, in searchable PDF Format, which were also approved by the Audit Committee and Board of Directors at their meeting held on **Wednesday, 14th November, 2018.**

Since the Limited Review Report is self-explanatory and has no modification/qualification, it needs no comments.

We are also in the process of filing the aforesaid Unaudited Financial Results in XBRL Format within the stipulated time and same shall also be hosted on the website of Company www.medicaps.com. The enclosed results will also be published in Hindi (Vernacular) & English newspaper.

You are requested to please take on record the aforesaid documents for reference and further needful.

Thanking You,
Yours Faithfully,
For, **MEDI-CAPS LTD.**


AYUSHI S. LOT
COMPANY SECRETARY &
COMPLIANCE OFFICER



Encl.: Unaudited Financial Results & Limited Review Report

Indore Office :

201, Pushpratna Paradise, 9/5, New Palasia, Indore 452 001 (INDIA)

Telefax No. : +91-731-4046321, 4041435, 4028148

**LIMITED REVIEW REPORT ON UNAUDITED STANDALONE HALF
YEARLY/ QUARTERLY FINANCIAL RESULTS OF MEDI-CAPS LIMITED**

To,
THE BOARD OF DIRECTORS OF
MEDI-CAPS LIMITED


1. We have reviewed the accompanying Unaudited Standalone Financial Results of **MEDI-CAPS LIMITED** ("the Company"), for the Half Year/Quarter ended Sept 30, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 interim financial reporting "IND AS 34" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

2. We conducted our review of the statement in accordance with the Standard on review engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Indore
Date: 14/11/2018

For: Rawka & Associates
(Chartered Accountants)




Venus Rawka
(Partner)

M. No. 429040

F. R. No. 021606C

MEDI-CAPS LIMITED

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-424242, Fax: 07292-407387

Website: www.medicaps.com Email: investors@medicaps.com CIN: L24232MP1983PLC002231

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 30th SEPTEMBER 2018

(Rs.in Lakhs except EPS)

Sr. No.	Particulars	3 Months ended on 30.09.2018 (Unaudited)	3 Months ended on 30.06.2018 (Unaudited)	3 Months ended on 30.09.2017 (Unaudited)	6 Months ended on 30.09.2018 (Unaudited)	6 Months ended on 30.09.2017 (Unaudited)	Previous Year ended on 31.03.2018 (Audited)
I	Income from operations						
	(a) Net sales	570.67	488.22	669.44	1058.89	1111.02	2235.35
	(b) Other operating income	17.69	12.24	14.77	29.93	23.25	65.74
	Total income from operation	588.36	500.46	684.21	1088.82	1134.27	2301.09
II	Other Income	2.23	0.48	(0.06)	2.72	(0.02)	1.55
III	Total income (I+II)	590.60	500.94	684.16	1091.54	1134.26	2302.65
IV	Expenses						
	a) Cost of material consumed	234.95	238.15	193.61	473.10	419.59	879.10
	b) Purchase of stock in trade	0.00	10.73	10.32	10.73	10.32	10.41
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	47.47	(51.69)	187.52	(4.22)	119.67	128.04
	d) Employee benefits expense	124.39	127.46	125.86	251.85	245.96	505.16
	e) Finance costs	0.35	0.39	0.00	0.74	0.00	0.00
	d) Power Cost	87.27	85.86	81.55	173.13	166.57	344.02
	e) Depreciation and amortisation expense	8.67	8.67	16.25	17.34	32.50	33.87
	f) Other expenses	76.02	70.89	51.75	146.91	109.30	325.67
	Total Expenses (IV)	579.12	490.47	666.86	1069.58	1103.91	2226.28
V	Profit / (Loss) before exceptional item & tax (III-IV)	11.48	10.47	17.30	21.96	30.35	76.37
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit/ (Loss) before tax (V-VI)	11.48	10.47	17.30	21.96	30.35	76.37
VIII	Tax expense						
	a) Current Tax	4.00	3.00	3.00	7.00	8.00	18.00
	b) Deferred Tax	0.00	0.00	0.00	0.00	0.00	2.02
	Total Tax Expenses	4.00	3.00	3.00	7.00	8.00	20.02
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	7.48	7.47	14.30	14.96	22.35	56.35
X	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00



XIII	Profit/(loss) for the period (IX+XII)	7.48	7.47	14.30	14.96	22.35	56.35
XIV	Other comprehensive income						
	(a) (i) items that will not be reclassified to statement of profit & loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax on items that will not be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00	0.00
	(b) (i) items that will be reclassified to statement of profit & loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax on items that will be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00	0.00
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	7.48	7.47	14.30	14.96	22.35	56.35
XVI	Paid-up equity share capital of the company (Face value Rs.10/- Per Share)	1246.99	1246.99	1246.99	1246.99	1246.99	1246.99
XVII	Reserves excluding revaluation reserves	0	0	0	0	0	0
XVIII	Earnings per equity share (for continuing operation)						
	a) Basic	0.06	0.05	0.11	0.12	0.18	0.45
	a) Diluted	0.06	0.05	0.11	0.12	0.18	0.45
XIX	Earnings per equity share (for discontinued operation)						
	a) Basic	0	0	0	0	0	0
	a) Diluted	0	0	0	0	0	0
XX	Earnings per equity share (for discontinued and continuing operation)						
	a) Basic	0.06	0.05	0.11	0.12	0.18	0.45
	a) Diluted	0.06	0.05	0.11	0.12	0.18	0.45



2 The standalone Statement of Assets & Liabilities is as under:

(Rs. in Lacs)

	Particulars	As at	
		6 Month ended on 30/09/2018	12 Month ended on 31/03/2018
		(Unaudited)	(Audited)
I.	Assets		
(1)	Non-Current Assets		
	(a) Property, Plant and Equipment	376.07	393.40
	(b) Capital work-in-progress	0.00	0.00
	(c) Investment Property	4629.93	4571.85
	(d) Goodwill	0.00	0.00
	(e) Other Intangible assets	0.00	0.00
	(f) Intangible assets under development	0.00	0.00
	(g) Biological Assets other than bearer plants	0.00	0.00
	(h) Financial Assets		
	(i) Investments	0.00	0.00
	(ii) Trade receivables	0.00	0.00
	(iii) Loans	0.00	0.00
	(iv) Others (to be specified)	0.00	0.00
	(i) Deferred tax assets (net)	0.00	0.00
	(j) Other non-current assets	45.25	44.26
(2)	Current assets		
	(a) Inventories	646.41	576.18
	(b) Financial Assets		
	(i) Investments	516.69	516.69
	(ii) Trade receivables	684.44	694.07
	(iii). Cash and cash equivalents	2.26	1.90
	(iv) Bank balances other than (iii) above	245.68	202.45
	(v) Loans	0.00	0.00
	(vi) Others (to be specified)	0.00	0.00
	(c) Current Tax Assets (Net)	0.00	0.00
	(d) Other current assets	197.02	181.11
	Total Assets	7343.75	7181.92
II.	EQUITY AND LIABILITIES		
	EQUITY		
	(a) Equity Share Capital	1247.00	1247.00
	(b) Other Equity	5459.63	5444.66



LIABILITIES		
(1) Non-Current Liabilities		
(a) Financial Liabilities	0.00	0.00
(i) Borrowings	0.00	0.00
(ii) Trade payables	0.00	0.00
a) total outstanding dues of micro enterprises and small enterprises; and	0.00	0.00
b) total outstanding dues of creditor other than micro enterprises and small enterprises;	0.00	0.00
(iii) Other financial liabilities (other than those specified in item (b), to be specified)	0.00	0.00
(b) Provisions	117.62	119.54
(c) Deferred tax liabilities (Net)	40.71	40.71
(2) Current Liabilities		
(a) Financial Liabilities	0.00	0.00
(i) Borrowings	14.86	17.46
(ii) Trade payables	278.51	147.48
a) total outstanding dues of micro enterprises and small enterprises; and	51.7	26.54
b) total outstanding dues of creditor other than micro enterprises and small enterprises;	<u>226.81</u>	<u>120.94</u>
(iii) Other financial liabilities (other than those specified in item (b),	0.00	0.00
(b) Other current liabilities	178.42	147.07
(c) Provisions	0.00	0.00
(d) Current Tax Liabilities (Net)	7.00	18.00
Total Equity and Liabilities	7343.75	7181.92



Notes:

1. The above results were reviewed by the Audit Committee and then approved by the Board at their respective meeting held on 14.11.2018. The statutory auditors of the company have carried out limited review of the unaudited results for the quarter/half year ended 30.09.2018.
2. The Company adopted Indian Accounting Standard ("Ind AS") from 01.04.2017 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial reporting" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under.
3. The financial results for the quarter ended 30.09.2018 have not been reviewed by the Statutory auditors. However, the management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of the Company's affairs.
4. The Company is primarily engaged in manufacturing of empty hard gelatin capsules and other activities revolving around the same.
5. As such there is no separate reportable operating segment as defined by Ind AS -108 - " Operating Segments".
6. Previous quarter's figures have been regrouped/reclassified where necessary.
7. IND AS 115 "Revenue from Contract with Customers" is mandatory for reporting periods beginning on or after 1st April, 2018 and replaces the existing revenue recognition requirements based on management assessment, the adoption of the standard did not have any material impact to the financial results of the company.
8. Excise duty on sales was included under Revenue from operations and disclosed separately under Expenses up to all reporting periods ending 30th June 2017. However, after implementation of Goods and Service Tax (GST) from 1st July, 2017, this is no longer relevant.

PLACE : PITHAMPUR
DATE : 14/11/2018

FOR, MEDI-CAPS LIMITED

KUSUM MITTAL
WHOLE TIME DIRECTOR
DIN: 00035356

